Abstract: Objective To observe the curative effect and safety of danshen injection combined with febuxostat in the treatment of patients with chronic uric acid nephropathy. Methods Ninety-four patients with chronic uric acid nephropathy were randomly divided into control group and treatment group with forty-seven cases per group. The control group was given febuxostat 40 mg, qd, po, and the treatment group was given danshen injection 30 ml, qd, ivgtt + febuxostat 40 mg, qd, po. After 8 weeks treatment, the clinical efficacy and occurrence of adverse drug reactions were observed. The levels of renal function, blood lipids and sex hormones were compared. Results The total effective rate 91.49% in treatment group was higher than the control group (P<0.05). The levels of serum creatinine (Scr), blood urea nitrogen (BUN), uric acid (UA), 24 h urine protein (UPRO), triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), estradiol (E2) and testosterone (T) in treatment group were lower than the control group, and the levels of glomerular filtration rate (eGFR) and high-density lipoprotein (HDL) were higher than the control group (P<0.05). The levels of prolactin (PRL) in treatment group and control group was no significant (P>0.05). The adverse drug reactions were mainly abnormal liver function, nausea, joint pain and rashes, the incidence of adverse drug reactions in treatment group and control group were 12.77% and 8.51%, respectively (P>0.05). Conclusion The danshen injection combined with febuxostat in the treatment of chronic uric acid nephropathy have significantly curative effect, can protect renal function, improve the blood lipid index and sex hormone levels, and have no increasing the adverse drug reactions.